NCT04455555

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 294 (actual)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The efficacy and safety of rotigotine in the treatment of patients with early stage of primary Parkinson's disease

Detailed description

To evaluate the efficacy and safety of rotigotine sustained release microspheres therapy by injection in the treatment of patients with early stage of primary Parkinson's disease

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	LY03003( the name of rotigotine)	LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
OTHER	Placebo	Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.

Timeline

• Start date: 2018-08-01
• Primary completion: 2019-02-01
• Completion: 2019-02-01
• First posted: 2020-07-02
• Last updated: 2020-07-02

Locations

1 site across 1 country: China